Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Research & Development: 2009-2024

Historic Research & Development for Fortress Biotech (FBIO) over the last 16 years, with Dec 2024 value amounting to $56.6 million.

  • Fortress Biotech's Research & Development fell 97.80% to $208,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 61.28%. This contributed to the annual value of $56.6 million for FY2024, which is 44.34% down from last year.
  • As of FY2024, Fortress Biotech's Research & Development stood at $56.6 million, which was down 44.34% from $101.7 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Research & Development registered a high of $134.9 million during FY2022, and its lowest value of $56.6 million during FY2024.
  • Moreover, its 3-year median value for Research & Development was $101.7 million (2023), whereas its average is $97.8 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 101.01% in 2021, then plummeted by 44.34% in 2024.
  • Yearly analysis of 5 years shows Fortress Biotech's Research & Development stood at $64.1 million in 2020, then skyrocketed by 101.01% to $128.9 million in 2021, then grew by 4.66% to $134.9 million in 2022, then declined by 24.56% to $101.7 million in 2023, then slumped by 44.34% to $56.6 million in 2024.